License Agreements - Vaccine Products License (Details) - Vaccine license and development agreement with TDT - Vaccine Products and Vaccine Diagnostics	Apr. 10, 2020 USD ($) item Milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment of license agreement fees	$ 4,000,000
Annual maintenance fees	$ 400,000
Unpaid annual maintenance fees, short term debt interest rate (%)	1.50%
Number of developmental and regulatory milestone payments for first product development \| Milestone	4
Maximum aggregate milestone commitment fund for first product development	$ 12,000,000
Number of developmental and regulatory milestone payments for each additional product development \| Milestone	4
Maximum milestone commitment fund for each additional product development	$ 6,000,000
Liminatus Pharma, LLC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment of license agreement fees	4,000,000
Annual maintenance fees	$ 400,000
Unpaid annual maintenance fees, short term debt interest rate (%)	1.50%
Number of developmental and regulatory milestone payments for first product development \| item	4
Maximum aggregate milestone commitment fund for first product development	$ 12,000,000
Number of developmental and regulatory milestone payments for each additional product development \| item	4
Maximum milestone commitment fund for each additional product development	$ 6,000,000
Maximum \| Liminatus Pharma, LLC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of years from first commercial sale of products (in years)	10 years
Net sales of period from first commercial sale until patent expires \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)	10.00%
Net sales of period from first commercial sale until patent expires \| Minimum \| Liminatus Pharma, LLC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)	10.00%
Net sales of period from first commercial sale until patent expires \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)	15.00%
Net sales of period from first commercial sale until patent expires \| Maximum \| Liminatus Pharma, LLC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)	15.00%
10 years from first commercial sale of products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of years from first commercial sale of products (in years)	10 years
10 years from first commercial sale of products \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)	5.00%
10 years from first commercial sale of products \| Minimum \| Liminatus Pharma, LLC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)	5.00%
10 years from first commercial sale of products \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)	9.00%
10 years from first commercial sale of products \| Maximum \| Liminatus Pharma, LLC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)	9.00%

Amount of maximum aggregate milestone commitment fund for first product development.

No definition available.

Name:	limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment
Namespace Prefix:	limn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of maximum milestone commitment fund for each additional product development.

+ References

No definition available.

+ Details

Name:	limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment
Namespace Prefix:	limn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of milestone developmental and regulatory milestone payments for each additional product development.

+ References

No definition available.

+ Details

Name:	limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment
Namespace Prefix:	limn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of milestone developmental and regulatory milestone payments for first product development.

+ References

No definition available.

+ Details

Name:	limn_NumberOfMilestonePaymentsForFirstProductDevelopment
Namespace Prefix:	limn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of years from the first commercial sale of CAR-T product or CAR-T Diagnostic.

+ References

No definition available.

+ Details

Name:	limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts
Namespace Prefix:	limn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of royalty fees

+ References

No definition available.

+ Details

Name:	limn_RoyaltyFeesPercentage
Namespace Prefix:	limn_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of interest rate of short-term debt being converted from the unpaid annual maintenance fees.

+ References

No definition available.

+ Details

Name:	limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate
Namespace Prefix:	limn_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of upfront payment of license agreement fee.

+ References

No definition available.

+ Details

Name:	limn_UpfrontPaymentOfLicenseAgreementFees
Namespace Prefix:	limn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cost of maintenance incurred and directly related to good produced and service rendered.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_CostMaintenance
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=limn_VaccineProductsAndVaccineDiagnosticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=limn_LiminatusPharmaLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: